Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 8.46
OGXI's Cash to Debt is ranked higher than
69% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. OGXI: 8.46 )
OGXI' s 10-Year Cash to Debt Range
Min: 0.88   Max: No Debt
Current: 8.46

Equity to Asset 0.67
OGXI's Equity to Asset is ranked higher than
73% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. OGXI: 0.67 )
OGXI' s 10-Year Equity to Asset Range
Min: -2.81   Max: 0.92
Current: 0.67

-2.81
0.92
F-Score: 1
Z-Score: 1.06
M-Score: 2.29
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -118.22
OGXI's Operating margin (%) is ranked higher than
67% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. OGXI: -118.22 )
OGXI' s 10-Year Operating margin (%) Range
Min: -48696   Max: 9.64
Current: -118.22

-48696
9.64
Net-margin (%) -106.58
OGXI's Net-margin (%) is ranked higher than
67% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. OGXI: -106.58 )
OGXI' s 10-Year Net-margin (%) Range
Min: -46544   Max: 10.24
Current: -106.58

-46544
10.24
ROE (%) -85.59
OGXI's ROE (%) is ranked higher than
56% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. OGXI: -85.59 )
OGXI' s 10-Year ROE (%) Range
Min: -148.97   Max: 10.12
Current: -85.59

-148.97
10.12
ROA (%) -57.19
OGXI's ROA (%) is ranked higher than
58% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. OGXI: -57.19 )
OGXI' s 10-Year ROA (%) Range
Min: -278.13   Max: 6.34
Current: -57.19

-278.13
6.34
ROC (Joel Greenblatt) (%) -2943.92
OGXI's ROC (Joel Greenblatt) (%) is ranked higher than
56% of the 868 Companies
in the Global Biotechnology industry.

( Industry Median: -189.80 vs. OGXI: -2943.92 )
OGXI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -25254.55   Max: 54.41
Current: -2943.92

-25254.55
54.41
Revenue Growth (%) 1.70
OGXI's Revenue Growth (%) is ranked higher than
76% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -0.40 vs. OGXI: 1.70 )
OGXI' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 628.7
Current: 1.7

0
628.7
EBITDA Growth (%) 4.60
OGXI's EBITDA Growth (%) is ranked higher than
85% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.60 vs. OGXI: 4.60 )
OGXI' s 10-Year EBITDA Growth (%) Range
Min: -74.3   Max: 104.5
Current: 4.6

-74.3
104.5
EPS Growth (%) 6.60
OGXI's EPS Growth (%) is ranked higher than
86% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. OGXI: 6.60 )
OGXI' s 10-Year EPS Growth (%) Range
Min: -74.7   Max: 96.2
Current: 6.6

-74.7
96.2
» OGXI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

OGXI Guru Trades in

Q2 2013

OGXI Guru Trades in Q2 2013

Jim Simons 33,100 sh (New)
» More
Q3 2013

OGXI Guru Trades in Q3 2013

Jim Simons 52,200 sh (+57.7%)
» More
Q4 2013

OGXI Guru Trades in Q4 2013

Jim Simons 84,800 sh (+62.45%)
» More
» Details

Insider Trades

Latest Guru Trades with OGXI

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2011-06-30 Sold Out $15.29 - $18.64 $ 10.43-36%0
Jean-Marie Eveillard 2011-03-31 Reduce -41.77%0.01%$15.0699 - $17.31 $ 10.43-35%84371
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.10
OGXI's P/B is ranked higher than
68% of the 787 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. OGXI: 4.10 )
OGXI' s 10-Year P/B Range
Min: 0.14   Max: 9
Current: 4.1

0.14
9
P/S 5.10
OGXI's P/S is ranked higher than
74% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 10.38 vs. OGXI: 5.10 )
OGXI' s 10-Year P/S Range
Min: 0.23   Max: 47.95
Current: 5.1

0.23
47.95
EV-to-EBIT 12.30
OGXI's EV-to-EBIT is ranked higher than
76% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. OGXI: 12.30 )
OGXI' s 10-Year EV-to-EBIT Range
Min: 11.4   Max: 15.9
Current: 12.3

11.4
15.9

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.40
OGXI's Price/Net Cash is ranked higher than
63% of the 476 Companies
in the Global Biotechnology industry.

( Industry Median: 9.10 vs. OGXI: 7.40 )
OGXI' s 10-Year Price/Net Cash Range
Min: 0.75   Max: 10.21
Current: 7.4

0.75
10.21
Price/Net Current Asset Value 5.60
OGXI's Price/Net Current Asset Value is ranked higher than
76% of the 520 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. OGXI: 5.60 )
OGXI' s 10-Year Price/Net Current Asset Value Range
Min: 0.75   Max: 10.21
Current: 5.6

0.75
10.21
Price/Tangible Book 4.10
OGXI's Price/Tangible Book is ranked higher than
72% of the 727 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. OGXI: 4.10 )
OGXI' s 10-Year Price/Tangible Book Range
Min: 0.5   Max: 17.15
Current: 4.1

0.5
17.15
Price/Median PS Value 0.80
OGXI's Price/Median PS Value is ranked higher than
78% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. OGXI: 0.80 )
OGXI' s 10-Year Price/Median PS Value Range
Min: 0.13   Max: 277.09
Current: 0.8

0.13
277.09
Earnings Yield (Greenblatt) 8.10
OGXI's Earnings Yield (Greenblatt) is ranked higher than
77% of the 379 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. OGXI: 8.10 )
OGXI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 6.3   Max: 8.8
Current: 8.1

6.3
8.8
Forward Rate of Return (Yacktman) -17.43
OGXI's Forward Rate of Return (Yacktman) is ranked higher than
70% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. OGXI: -17.43 )
OGXI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -76.3   Max: -61.1
Current: -17.43

-76.3
-61.1

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:SP4A.Germany
OncoGenex Pharmaceuticals, Inc., a Delaware corporation was incorporated in October 1991. It is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. It has three product candidates in its pipeline, custirsen, OGX-427 and OGX-225, each of which has a distinct mechanism of action and represents a unique opportunity for cancer drug development. Of the product candidates in its pipeline, custirsen and OGX-427 are clinical-stage assets. The Company's product candidate, custirsen, OGX-427, and OGX-225 focus on mechanisms of treatment resistance in cancer patients and are designed to block the production of specific proteins that promote survival of tumor cells and are over-produced in response to a variety of cancer treatments. The Company's aim in targeting these particular proteins is to disable the tumor cell's adaptive defenses, thereby rendering the tumor cells more susceptible to attack with a variety of cancer therapies. Custirsen is its product candidate designed to inhibit the production of clusterin, an antiapoptotic, stress-induced protein which will promote the survival of cancer cells when overexpressed in a variety of tumors. The Company and collaborating investigators have conducted five phase 2 clinical trials to evaluate the ability of custirsen to enhance the effects of therapy in prostate, non-small cell lung and breast cancers. OGX-427 is its product candidate that is designed to inhibit production of heat shock protein 27, or Hsp27, a cell-survival protein expressed in many types of cancers including prostate, bladder, breast and non-small cell lung cancer. Hsp27 expression is stress-induced, including by many anti-cancer therapies. OGX-225 is a product candidate in pre-clinical development that is designed to inhibit production of both Insulin Growth Factor Binding Protein-2, or IGFBP-2, and Insulin Growth Factor Binding Protein-5, or IGFBP-5. Increased IGFBP-2 or IGFBP-5 production is observed in many human cancers, including prostate, non-small cell lung, breast, ovarian, bladder, pancreatic and colon, as well as acute myeloid leukemia, acute lymphoblastic leukemia, neuroblastoma, glioma and melanoma. It faces significant competition from many pharmaceutical, biopharmaceutical and biotechnology companies that are researching and marketing products.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide